<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 07, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078168</url>
  </required_header>
  <id_info>
    <org_study_id>ADAM</org_study_id>
    <secondary_id>2009-011881-27</secondary_id>
    <nct_id>NCT01078168</nct_id>
  </id_info>
  <brief_title>Alzheimer`s Disease Acitretin Medication</brief_title>
  <acronym>ADAM</acronym>
  <official_title>Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer Forschungsinitiative e.V. (AFI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trials investigates the changes of cerebral spinal fluid APPSα levels under oral therapy
      with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease.The present
      study aims to demonstrate an enhancement of the α-secretase activity by acitretin as measured
      by increased CSF APPSα levels in human AD. Second, the safety and tolerability of acitretin
      in AD patients should be proven.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in CSF APPSα concentration at Visit 3 compared to Baseline</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Alzheimer Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin</intervention_name>
    <description>30mg per day from Day 1 to Day 28</description>
    <other_name>Vareniclin (Champix)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate AD (NINCDS-ADRDA criteria)

          -  MMSE: 27-14 points

          -  Geriatric Depression Scale ≤ 14

        Exclusion Criteria:

          -  hereditary cognitive impairment

          -  known history of brain injuries

          -  Insufficient German language skills

          -  actual treatment with other potential disease modifying drugs of AD

          -  multimorbidity or significant organ (esp. liver or renal) dysfunction

          -  evidence of Non-AD neurodegenerative disorder (e.g. Parkinson)

          -  contraindication to acitretin such as osteoporosis, hypoalbuminaemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Fellgiebel, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Dr. Lorscheider, Clinical coordinator</last_name>
    <phone>+49-6131-17-6103</phone>
    <email>lorscheider@psychiatrie.klinik.uni-mainz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas PD Dr. Fellgiebel, Coordinating investigator</last_name>
    <phone>+49-6131-17-2525</phone>
    <email>fellgiebel@psychiatrie.klinik.uni-mainz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Lorscheider, Dr. med.</last_name>
      <phone>+49-6131-17-6103</phone>
      <email>lorscheider@psychiatrie.klinik.uni-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Andresa Fellgiebel, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Lorscheider, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anke Thuemler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>September 14, 2010</lastchanged_date>
  <firstreceived_date>March 1, 2010</firstreceived_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>September 14, 2010</last_update_submitted>
  <last_update_submitted_qc>September 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <name_title>PD Dr. Andreas Fellgiebel</name_title>
    <organization>University Medical Center of the Johannes Gutenberg-University Mainz; Department of Psychiatrie and Psychotherapy</organization>
  </responsible_party>
  <keyword>Alzheimer`s Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acitretin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

